Mouse models of human cancer as tools in drug development.
Histologically accurate mouse models of human cancers generated by somatic or germline genetic modification strategies recapitulate the genetic alterations found in human tumors. In this issue of Cancer Cell, test a novel signaling inhibitor in a genetically defined mouse medulloblastoma and show the utility of these models in drug development. They demonstrate that targeting signaling components downstream of tumor initiating mutations can be an effective therapeutic strategy for solid tumors.
Holland
Eric C
EC
Memorial Sloan-Kettering Cancer Center, Departments of Surgery (Neurosurgery), Neurology, and Cell Biology and Genetics, 1275 York Avenue, New York, NY 10021, USA. hollande@mskcc.org
D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics*; D004195:Disease Models, Animal; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D018095:Germ-Line Mutation; D008527:Medulloblastoma / Q000188:drug therapy / Q000235:genetics*; D051379:Mice; D008822:Mice, Transgenic; D009374:Neoplasms, Experimental; D015398:Signal Transduction / Q000187:drug effects